Whitehawk Therapeutics (WHWK) shares were sharply higher Thursday after the company formed a multi-year collaboration with Tempus AI (TEM) to leverage Tempus' real-world dataset to advance biomarker-driven research and further Whitehawk Therapeutics' oncology pipeline, Tempus said.

The collaboration will focus on Whitehawk Therapeutics' antibody drug conjugates portfolio, which includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers, the company said.

Shares of Tempus AI and Whitehawk were up 5.3% and 54.7%, respectively, in early trading.

Price: 3.28, Change: +1.17, Percent Change: +55.45